AstraZeneca’s Fasenra asthma drug shows promise for COPD treatment

AstraZeneca's Fasenra (benralizumab) has recently been approved by the FDA for treating severe asthma in children aged 6 to 11 with the eosinophilic phenotype. A phase III clinical trial is now underway to test the effectiveness of Fasenra in COPD.